CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Time course of regorafenib-associated adverse events in the phase III CORRECT study
DOI 10.1055/s-0033-1352701
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Denzlinger, A Grothey, AF Sobrero, E van Cutsem, S Siena, A Falcone, M Ychou, Y Humblet, O Bouche, L Mineur, C Barone, A Adenis, J Tabernero, T Yoshino, HJ Lenz, RM Goldberg, F Cihon, A Wagner, D Laurent
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Regorafenib (REG) is an oral multikinase inhibitor that has recently demonstrated significant overall survival benefit vs. placebo in the randomized Phase III CORRECT study. Methods: We examined the time course of adverse events (AEs) in the CORRECT study. Results: The safety population comprised 753 patients (pts): REG n = 500; placebo n = 253. The mean treatment duration was 12.1 ± 9.7 weeks in the REG group…
Zitieren
Zitierempfehlung
C Denzlinger, A Grothey, AF Sobrero, E van Cutsem, S Siena, A Falcone, M Ychou, Y Humblet, O Bouche, L Mineur, C Barone, A Adenis, J Tabernero, T Yoshino, HJ Lenz, RM Goldberg, F Cihon, A Wagner, D Laurent (2013) Time course of regorafenib-associated adverse events in the phase III CORRECT study. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0033-1352701
Mit CareLit weiterarbeiten